Pharmacoeconomic evaluation of hypothetical over-the-counter angiotensin-converting enzyme (ACE) inhibitors for the prevention of stroke in patients with grade I hypertension

Takeshi Uchikura, Nobuyuki Yokoi, Masayuki Hashiguchi, Mayumi Mochizuki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The effectiveness and safety of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension have been confirmed during long-term use. Therefore, ACE inhibitors were selected as one candidate for the switch from ethical drugs to over-the-counter (OTC) medications. The objective of this study was to perform a cost-effectiveness analysis if ACE inhibitors were switched to OTC medications and used by grade I hypertension patients in Japan. We conducted a cost-effectiveness analysis from a social perspective over a lifetime horizon using a Markov Model in 50- year-old men and women with grade I hypertension. They were divided into 3 groups: 1) untreated group; 2) consultation group visiting a clinic and receiving prescriptions for ACE inhibitors; and 3) OTC group purchasing OTC ACE inhibitors. The cost of OTC medications was estimated based on a previous study of willingness to pay (¥7,237/month). Average life expectancies in both the OTC and consultation groups were 20.20 for men and 22.63 for women, while in the untreated group it was 19.97 for men and 22.47 for women. Incremental costs per expected life-year (ICER) were ¥1,743,557 for men and ¥8,647,069 for women in the OTC group and ¥3,819,861 for men and ¥9,639,844 for women in the consultation group. These results suggest that longer life expectancies can be achieved with ACE inhibitors, and the total cost is decreased using OTC ACE inhibitors compared with ethical drugs. OTC ACE inhibitors therefore appear be a useful alternative for patients who do not have time to visit a clinic regularly.

Original languageEnglish
Pages (from-to)571-580
Number of pages10
JournalYakugaku Zasshi
Volume131
Issue number4
DOIs
Publication statusPublished - 2011

Fingerprint

Pharmaceutical Economics
Angiotensin-Converting Enzyme Inhibitors
Stroke
Hypertension
Referral and Consultation
Life Expectancy
Costs and Cost Analysis
Cost-Benefit Analysis
Group Purchasing
Nonprescription Drugs
Ambulatory Care
Prescriptions
Japan
Safety

Keywords

  • Angiotensin-converting enzyme (ACE) inhibitor
  • Cost-effectiveness
  • Hypertension
  • Over-the-counter (OTC) medication
  • Pharmacoeconomics
  • Stroke

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacoeconomic evaluation of hypothetical over-the-counter angiotensin-converting enzyme (ACE) inhibitors for the prevention of stroke in patients with grade I hypertension. / Uchikura, Takeshi; Yokoi, Nobuyuki; Hashiguchi, Masayuki; Mochizuki, Mayumi.

In: Yakugaku Zasshi, Vol. 131, No. 4, 2011, p. 571-580.

Research output: Contribution to journalArticle

@article{fdd81c41ddcf40a1879b4e25f1875a4b,
title = "Pharmacoeconomic evaluation of hypothetical over-the-counter angiotensin-converting enzyme (ACE) inhibitors for the prevention of stroke in patients with grade I hypertension",
abstract = "The effectiveness and safety of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension have been confirmed during long-term use. Therefore, ACE inhibitors were selected as one candidate for the switch from ethical drugs to over-the-counter (OTC) medications. The objective of this study was to perform a cost-effectiveness analysis if ACE inhibitors were switched to OTC medications and used by grade I hypertension patients in Japan. We conducted a cost-effectiveness analysis from a social perspective over a lifetime horizon using a Markov Model in 50- year-old men and women with grade I hypertension. They were divided into 3 groups: 1) untreated group; 2) consultation group visiting a clinic and receiving prescriptions for ACE inhibitors; and 3) OTC group purchasing OTC ACE inhibitors. The cost of OTC medications was estimated based on a previous study of willingness to pay (¥7,237/month). Average life expectancies in both the OTC and consultation groups were 20.20 for men and 22.63 for women, while in the untreated group it was 19.97 for men and 22.47 for women. Incremental costs per expected life-year (ICER) were ¥1,743,557 for men and ¥8,647,069 for women in the OTC group and ¥3,819,861 for men and ¥9,639,844 for women in the consultation group. These results suggest that longer life expectancies can be achieved with ACE inhibitors, and the total cost is decreased using OTC ACE inhibitors compared with ethical drugs. OTC ACE inhibitors therefore appear be a useful alternative for patients who do not have time to visit a clinic regularly.",
keywords = "Angiotensin-converting enzyme (ACE) inhibitor, Cost-effectiveness, Hypertension, Over-the-counter (OTC) medication, Pharmacoeconomics, Stroke",
author = "Takeshi Uchikura and Nobuyuki Yokoi and Masayuki Hashiguchi and Mayumi Mochizuki",
year = "2011",
doi = "10.1248/yakushi.131.571",
language = "English",
volume = "131",
pages = "571--580",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Pharmacoeconomic evaluation of hypothetical over-the-counter angiotensin-converting enzyme (ACE) inhibitors for the prevention of stroke in patients with grade I hypertension

AU - Uchikura, Takeshi

AU - Yokoi, Nobuyuki

AU - Hashiguchi, Masayuki

AU - Mochizuki, Mayumi

PY - 2011

Y1 - 2011

N2 - The effectiveness and safety of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension have been confirmed during long-term use. Therefore, ACE inhibitors were selected as one candidate for the switch from ethical drugs to over-the-counter (OTC) medications. The objective of this study was to perform a cost-effectiveness analysis if ACE inhibitors were switched to OTC medications and used by grade I hypertension patients in Japan. We conducted a cost-effectiveness analysis from a social perspective over a lifetime horizon using a Markov Model in 50- year-old men and women with grade I hypertension. They were divided into 3 groups: 1) untreated group; 2) consultation group visiting a clinic and receiving prescriptions for ACE inhibitors; and 3) OTC group purchasing OTC ACE inhibitors. The cost of OTC medications was estimated based on a previous study of willingness to pay (¥7,237/month). Average life expectancies in both the OTC and consultation groups were 20.20 for men and 22.63 for women, while in the untreated group it was 19.97 for men and 22.47 for women. Incremental costs per expected life-year (ICER) were ¥1,743,557 for men and ¥8,647,069 for women in the OTC group and ¥3,819,861 for men and ¥9,639,844 for women in the consultation group. These results suggest that longer life expectancies can be achieved with ACE inhibitors, and the total cost is decreased using OTC ACE inhibitors compared with ethical drugs. OTC ACE inhibitors therefore appear be a useful alternative for patients who do not have time to visit a clinic regularly.

AB - The effectiveness and safety of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension have been confirmed during long-term use. Therefore, ACE inhibitors were selected as one candidate for the switch from ethical drugs to over-the-counter (OTC) medications. The objective of this study was to perform a cost-effectiveness analysis if ACE inhibitors were switched to OTC medications and used by grade I hypertension patients in Japan. We conducted a cost-effectiveness analysis from a social perspective over a lifetime horizon using a Markov Model in 50- year-old men and women with grade I hypertension. They were divided into 3 groups: 1) untreated group; 2) consultation group visiting a clinic and receiving prescriptions for ACE inhibitors; and 3) OTC group purchasing OTC ACE inhibitors. The cost of OTC medications was estimated based on a previous study of willingness to pay (¥7,237/month). Average life expectancies in both the OTC and consultation groups were 20.20 for men and 22.63 for women, while in the untreated group it was 19.97 for men and 22.47 for women. Incremental costs per expected life-year (ICER) were ¥1,743,557 for men and ¥8,647,069 for women in the OTC group and ¥3,819,861 for men and ¥9,639,844 for women in the consultation group. These results suggest that longer life expectancies can be achieved with ACE inhibitors, and the total cost is decreased using OTC ACE inhibitors compared with ethical drugs. OTC ACE inhibitors therefore appear be a useful alternative for patients who do not have time to visit a clinic regularly.

KW - Angiotensin-converting enzyme (ACE) inhibitor

KW - Cost-effectiveness

KW - Hypertension

KW - Over-the-counter (OTC) medication

KW - Pharmacoeconomics

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=79953685220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953685220&partnerID=8YFLogxK

U2 - 10.1248/yakushi.131.571

DO - 10.1248/yakushi.131.571

M3 - Article

C2 - 21467797

AN - SCOPUS:79953685220

VL - 131

SP - 571

EP - 580

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 4

ER -